A Comparison of the Efficacy and Toxic Effects of Sustained- vs Immediate-Release Niacin in Hypercholesterolemic Patients
JAMAPublished 2 March 1994
James M. McKenney
Citations301
SJR quartileQ1
SJR score5.35
SNIP10.71
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The IR niacin is preferred for the management of hypercholesterolemia but can also cause significant adverse effects and should be given only to patients who can be carefully monitored by experienced health professionals.
Abstract
The SR form of niacin is hepatotoxic and should be restricted from use. The IR niacin is preferred for the management of hypercholesterolemia but can also cause significant adverse effects and should be given only to patients who can be carefully monitored by experienced health professionals.
Keywords
MedicinePharmacology, Toxicology and Pharmaceutics
Clinical ChemistryEstimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
32,475 Citations1972William T. Friedewald, Robert I. Levy +1 more
A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented and comparison of this suggested procedure with the more direct procedure, in which the ultracentrifuge is used, yielded correlation coefficients of .94 to .99.
JAMASummary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
27,886 Citations1993Scott M. Grundy
Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Multivariate Statistical Methods
5,617 Citations2008
New England Journal of MedicineRegression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B
2,166 Citations1990Greg Brown, John J. Albers +8 more
In men with coronary artery disease who were at high risk for cardiovascular events, intensive lipid-lowering therapy reduced the frequency of progression of coronary lesions, increased the frequencyof regression, and reduced the incidence of cardiovascular events.
Journal of the American College of CardiologyFifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
1,841 Citations1986Paul L. Canner, Kenneth G. Berge +5 more
The Coronary Drug Project was conducted to assess the long-term efficacy and safety of five lipid-influencing drugs in 8,341 men aged 30 to 64 years with electrocardiogram-documented previous myocardial infarction, and niacin treatment showed modest benefit in decreasing definite nonfatal recurrent myocardia but did not decrease total mortality.
JAMABeneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts
1,643 Citations1987David H. Blankenhorn
The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol hydrochloride and niacin therapy in 162 nonsmoking men aged 40 to 59 years with previous coronary bypass surgery.
BiometricsUnbalanced Repeated-Measures Models with Structured Covariance Matrices
1,346 Citations1986Robert I. Jennrich, Mark Schluchter
This work addresses the question of how to analyze unbalanced or incomplete repeated-measures data through maximum likelihood analysis using a general linear model for expected responses and arbitrary structural models for the within-subject covariances.
JAMARegression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia With Combined Drug Regimens
801 Citations1990John P. Kane
Reduction of low-density lipoprotein cholesterol levels can induce regression of atherosclerotic lesions of the coronary arteries in patients with familial hypercholesterolemia, and the anticipation of benefit from treatment applies to women and men alike.
Journal of Internal MedicinePronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid
447 Citations1989Lars A. Carlson, Anders Hamsten +1 more
Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid is reported.
MetabolismContrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
233 Citations1985Robert H. Knopp, Janice Ginsberg +7 more
This study compares the effects of time-release niacin with those of unmodified niacIn on lipoprotein lipids, including HDL2 and HDL3, apoproteins A-I and A-II, clinical chemistries, symptomatic side effects, and adherence to the medication regimen
DiabetesIncreased β-Cell Secretory Capacity as Mechanism for Islet Adaptation to Nicotinic Acid-Induced Insulin Resistance
180 Citations1989Steven E. Kahn, James C Beard +6 more
The pancreatic islet adapts to the prolonged insulin resistance induced by NA through a combination of increased insulin secretion and reduced glucagon secretion, which can be entirely explained by an increase in the secretory capacity of the β-cell.
The American Journal of MedicineHepatic toxicity of unmodified and time-release preparations of niacin
133 Citations1992Jeanne I. Rader, Richard J. Calvert +1 more
In doses that achieve equivalent reductions in serum lipids, hepatic toxicity occurred more frequently with time-release preparations than with unmodified preparations.
AtherosclerosisDifferential effects of nicotinic acid in subjects with different LDL subclass patterns
132 Citations1992H. Robert Superko, Ronald M. Krauss
Twenty-six subjects (20 male, 6 female) at high risk for CAD events were treated with moderate doses of nicotinic acid to investigate whether there was a differential lipoprotein response in patients with different LDL subclass patterns.
Annals of Internal MedicineFulminant Hepatic Failure after Ingestion of Sustained-Release Nicotinic Acid
119 Citations1989Gerard E. Mullin, Joel K. Greenson +1 more
Nicotinic acid is an effective, widely used treatment for hypercholesterolemia and Hepatotoxicity is a rare complication of therapy, which usually occurs with ingestion of more than 3 g of the substance per day.
The American Journal of MedicineHepatotoxicity associated with sustained-release niacin
99 Citations1992Thomas A. Dalton, Robert S. Berry
A patient is described who developed an acute illness characterized by hypothermia, hypotension, metabolic acidosis, and severe hepatic dysfunction 2 days after substitution of an SR preparation for a previously well-tolerated crystalline niacin.
Mayo Clinic ProceedingsNiacin-Induced Hepatitis: A Potential Side Effect With Low-Dose Time-Release Niacin
91 Citations1991Jeff Etchason, Todd D. Miller +5 more
Hepatitis developed in five patients who were taking low dosages (3 g/day or less) of time-release niacin and this manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacIn.
The American Journal of CardiologyEffect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio
81 Citations1989James Alderman, Richard C. Pasternak +4 more
Niacin can be administered in a fashion that is well tolerated, inexpensive and very effective in improving the cholesterol to HDL ratio.
The American Journal of MedicineHypercholesteremia and nicotinic acid
73 Citations1961Kenneth G. Berge, Richard W. P. Achor +3 more
The continued careful use of this agent in the investigative treatment of hypercholesteremia is warranted and may ultimately provide insight into the possible value of lowering elevated levels of cholesterol in the blood as a means of treatment or prevention of atherosclerosis.
The American Journal of MedicineNiacin revisited: Clinical observations on an important but underutilized drug
72 Citations1991Yaakov Henkin, Albert Oberman +2 more
The authors' experience supports the fact that regular niacin is a useful lipid-modifying drug and the availability of sustained-release niac in as a nonprescription drug is unjustified and should be reexamined.
PubMedAssessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). I. Use of a dietary monitoring tool.
72 Citations1980S R D Patricia Remmell, Diane D. Gorder +2 more
Using special forms supplied by MRFIT nutrition counselors, participants were able to self-monitor their dietary regimens and a food scoring system was developed in which positive points are assigned to high-saturated-fat foods and negative points to foods and high-polyunsaturated-Fat and low-cholesterol content.
JAMANicotinic Acid Treatment of Hypercholesteremia
70 Citations1961Norman A. Christensen
The most significant difference was the greater frequency and severity of side effects during treatment with the 3 sustained-action preparations, and this precluded the majority of patients from completing a 3-month period of treatment.
JAMARechallenge With Crystalline Niacin After Drug-Induced Hepatitis From Sustained-Release Niacin
66 Citations1990Yaakov Henkin
Three patients who developed hepatitis during treatment with sustained-release niacin were rechallenged with equivalent or higher doses of crystalline niacIn, with no evidence of recurring hepatocellular damage.
Archives of Internal MedicineEffect of Low-Dose Niacin on High-Density Lipoprotein Cholesterol and Total Cholesterol/High-Density Lipoprotein Cholesterol Ratio
58 Citations1988Myron H. Luria
Although often difficult to administer to patients, niacin deserves consideration as an inexpensive agent especially useful for elevating HDL cholesterol level and altering the total cholesterol/HDL cholesterol ratio.
Journal of Clinical GastroenterologyNicotinic Acid-Induced Fulminant Hepatic Failure
57 Citations1987G L Clementz, A. W. Holmes
This case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity.
The American Journal of CardiologyMarked benefit with sustained-release niacin therapy in patients with “isolated” very low levels of high-density lipoprotein cholesterol and coronary artery disease
52 Citations1992C.J. Lavie, Lois Mailander +1 more
The efficacy of sustained-release niacin therapy in CAD patients with very low levels of HDL cholesterol is assessed, including its effectiveness in a sub group with isolated low HDL cholesterol compared with a subgroup with hypertriglyceridemia.
Archives of Internal MedicineNiacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia
49 Citations1991Joseph M. Keenan
JAMAAcute Hepatic Failure Associated With the Use of Low-Dose Sustained-Release Niacin
40 Citations1990Howard N. Hodis
Digestive Diseases and SciencesJaundice due to nicotinic acid therapy
26 Citations1975Norman Einstein, Alfred L. Baker +2 more
A 22-year-old woman who was admitted with pruritus and marked jaundice had taken 3 g nicotinic acid along with several other vitamin preparations daily for several years, and a liver biopsy specimen showed hepatitis with submassive necrosis, as well as cholestasis and marked bile duct proliferation.
Journal of the American Geriatrics SocietyTreatment of Hypercholesterolemia: Comparison of Younger versus Older Patients Using Wax‐Matrix Sustained‐Release Niacin
20 Citations1992Joseph M. Keenan, Chul‐Young Bae +5 more
Comparisons of lipid response, side effect profile and toxicity of younger (<50 years) versus older (50 to 70 years) hypercholesterolemic subjects taking wax‐matrix sustained‐release niacin (Endur‐acin®) are compared.
AtherosclerosisNormalisation of the composition of very low density lipoprotein in hypertriglyceridemia by nicotinic acid
17 Citations1990Per Tornvall, Anders Hamsten +2 more
Large and small very low density lipoprotein particles were isolated by density gradient ultracentrifugation and characterized chemically in 8 patients with primary hypertriglyceridemia and the composition of both large and small VLDL particles changed towards potentially less atherogenic particles that were poorer in cholesteryl esters.
Annals of Internal MedicineNiacin and Hepatic Failure
13 Citations1989Robert H. Knopp
I read with interest the recent report by Mullin and associates on fulminant hepatic failure in a patient after ingestion of sustained-release nicotinic acid.
The American Journal of the Medical SciencesCase Report: Hepatitis and Hematemesis Complicating Nicotinic Acid Use
8 Citations1989Gary Ferenchick, David R. Rovner
The authors report the case of a previously healthy 20-year-old man who developed hematemesis and hepatitis 1 week after self-initiating the daily consumption of 6 g of nicotinic acid, and suggest a possible causal relationship between nicotinics acid consumption and his presenting problems.
Mayo Clinic ProceedingsRediscovery of Crystalline Niacin
4 Citations1991P J Palumbo
Recently, its beneficial effects have been rediscovered, and niacin has been used more widely than in the past to control hyperlipidemia-particularly hypertriglyceridemia and hypo-a-lipoproteinemia.
Annals of Internal MedicineAll Niacin Is Not the Same
2 Citations1991Philip H. Frost
Niacin (nicotinic acid) is recognized as a drug of first choice for the treatment of the hyperlipidemias and is produced as a dietary supplement, but it has become an over-the-counter drug.